Amgen (AMGN) announces positive results from a study of its cholesterol-fighting human...
Monday, March 26, 2012, 6:53 AM ETAmgen (AMGN) announces positive results from a study of its cholesterol-fighting human monoclonal antibody AMG 145. The treatment reduces so-called bad cholesterol by up to 81%, according to data. Phase II results are due out later this year as Amgen tries to shoulder into the high-stakes Lipitor vs. generics battle.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles